drugset
drugset / Trial / NCT05135663

Extension Study of NS-089/NCNP-02 in DMD

NCT05135663 ↗

Phase 2 Active not recruiting 6 enrolled Nippon Shinyaku Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is the extension study of NS-089/NCNP-02 (Study NCNP/DMT02), which is designed to assess the safety, tolerability and efficacy of NS-089/NCNP-02 in patients with Duchenne muscular dystrophy (DMD).

Timeline

Start
2021-06-23
Primary completion
2027-04-30
Completion
2027-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject brogidirsen Unknown 40 mg/kg —
Subject brogidirsen Unknown 80 mg/kg —

Indications

Duchenne muscular dystrophy